Weekly Digest – May 2025 Weekly Digest – May 2025 09 May 2025: Minghui Pharmaceutical announces strategic partnership and licensing agreement with Qilu Pharmaceutical to develop B7-H3 ADC in greater china Minghui Pharmaceutical has entered an exclusive licensing and collaboration […]
Weekly Digest – May 2025 Weekly Digest – May 2025 15 May 2025: SparX Biopharmaceutical announces research agreement with Mitsubishi Tanabe Pharma America to advance novel antibody-drug conjugates SparX Biopharmaceutical has entered a research agreement with Mitsubishi Tanabe Pharma America […]
Weekly Digest – May 2025 Weekly Digest – May 2025 20 May 2025: Antengene enters into a global clinical collaboration with MSD to evaluate ATG-022 (CLDN18.2 ADC) in combination with KEYTRUDA (Pembrolizumab) Antengene has entered a global clinical collaboration with […]
Weekly Digest – May 2025 Weekly Digest – May 2025 13 May 2025: LigaChem Biosciences partners with Y Biologics for antibody technology LigaChem has secured exclusive global rights to develop antibody-drug conjugates (ADCs) using a novel antibody from Y Biologics, […]
Weekly Digest – May 2025 Weekly Digest – May 2025 08 May 2025: AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low breast cancer in India AstraZeneca received CDSCO approval in India to import and sell […]
Weekly Digest – May 2025 Weekly Digest – May 2025 06 May 2025: Adcentrx Therapeutics granted Fast Track Designation for ADRX-0706 nectin-4 ADC for the treatment of advanced cervical cancer Adcentrx Therapeutics received FDA Fast Track designation for its lead […]
Weekly Digest – May 2025 Weekly Digest – May 2025 06 May 2025: IDEAYA Biosciences announces US FDA IND-clearance for IDE849, a potential first-in-class DLL3 TOP1 ADC, for a Phase 1 study in solid tumors IDEAYA Biosciences received FDA clearance […]
Weekly Digest – May 2025 Weekly Digest – May 2025 07 May 2025: ENHERTU (Trastuzumab deruxtecan) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer […]
Weekly Digest – May 2025 Weekly Digest – May 2025 05 May 2025: VERAXA Biotech enters co-discovery alliance with OmniAb for a novel bispecific antibody drug conjugate program VERAXA Biotech has entered into a co-discovery alliance with OmniAb to develop […]
Weekly Digest – May 2025 Weekly Digest – May 2025 06 May 2025: Formosa Pharmaceuticals and Almac Discovery announce licensing agreement for ALM-401, a first-in-class Bispecific ADC targeting EGFR/ROR1 for the treatment of solid tumors Formosa Pharmaceuticals has secured exclusive […]
